Insider Selling: Blueprint Medicines (BPMC) Insider Sells 2,300 Shares of Stock

Blueprint Medicines (NASDAQ:BPMC) insider Marion Dorsch sold 2,300 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $100.07, for a total transaction of $230,161.00. Following the completion of the transaction, the insider now owns 2,300 shares of the company’s stock, valued at approximately $230,161. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Blueprint Medicines stock opened at $93.29 on Wednesday. Blueprint Medicines has a 12 month low of $34.38 and a 12 month high of $109.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.98 and a quick ratio of 15.98.

How to Become a New Pot Stock Millionaire

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.16). The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $5.28 million. Blueprint Medicines had a negative net margin of 691.30% and a negative return on equity of 38.79%. The business’s quarterly revenue was down 78.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) earnings per share. equities research analysts anticipate that Blueprint Medicines will post -4.85 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the stock. BidaskClub downgraded shares of Blueprint Medicines from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Friday, February 23rd. Finally, Cowen reissued a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $84.20.

Institutional investors and hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new position in Blueprint Medicines in the 3rd quarter valued at $6,967,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Blueprint Medicines by 57.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 680 shares in the last quarter. California Public Employees Retirement System purchased a new stake in shares of Blueprint Medicines during the 2nd quarter worth $314,000. Virtus Fund Advisers LLC purchased a new stake in shares of Blueprint Medicines during the 4th quarter worth $348,000. Finally, Geode Capital Management LLC boosted its position in shares of Blueprint Medicines by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 369,391 shares of the biotechnology company’s stock worth $27,855,000 after purchasing an additional 35,455 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Blueprint Medicines (BPMC) Insider Sells 2,300 Shares of Stock” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/11/insider-selling-blueprint-medicines-corp-bpmc-insider-sells-2300-shares-of-stock.html.

About Blueprint Medicines

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply